Recent Quotes (30 days)

You have no recent quotes
chg | %

Mirati Therapeutics Inc  

(Public, TSE:MYG)   Watch this stock  
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.50 - 22.00
Open     -
Vol / Avg. 0.00/963.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.95
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -92.43% -89.17%
Return on average equity -101.75% -162.00%
Employees 33 -
CDP Score - -


9393 Towne Centre Dr Ste 200
SAN DIEGO, CA 92121-3070
United States - Map
+1-858-3323410 (Phone)
+1-888-2115624 (Fax)

Website links


Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. The Company's pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

Officers and directors

Rodney W. Lappe Ph.D. Independent Chairman of the Board
Age: 60
Charles M. Baum M.D., Ph.D. President, Chief Executive Officer, Director
Age: 57
Mark J. Gergen J.D. Chief Operating Officer, Executive Vice President
Age: 52
Isan Chen M.D. Chief Medical and Development Officer, Executive Vice President
Age: 52
James Christensen Senior Vice President, Chief Scientific Officer
Age: 46
Jamie A. Donadio Vice President - Finance
Age: 39
Michael G. Grey Director
Age: 62
Henry J. Fuchs M.D.,Ph.D. Independent Director
Age: 57
Craig A Johnson Independent Director
Age: 53
William R. Ringo Independent Director
Age: 69